Cellosaurus logo
expasy logo

Cellosaurus M14 (CVCL_1395)

[Text version]
Cell line name M14
Synonyms M14-MEL; UCLA-SO-M14; UCLA SO M14; UCLA-SO-14; UCLASO-M14; Melanoma 14; M-14
Accession CVCL_1395
Resource Identification Initiative To cite this cell line use: M14 (RRID:CVCL_1395)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Population: Caucasian.
Doubling time: 26.3 hours (NCI-DTP=M14).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=19799798; PubMed=29492214; Cosmic-CLP=905975; DepMap=ACH-002159).
  • Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=19799798; PubMed=29492214).
  • Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=19799798; PubMed=29492214).
  • Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=17088437; PubMed=18277095; Cosmic-CLP=905975; DepMap=ACH-002159).
HLA typing Source: PubMed=15748285
Class I
Class II
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0
East Asian, North0
East Asian, South1.08
South Asian0
European, North67.89
European, South30.39
Disease Amelanotic melanoma (NCIt: C3802)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_6279 (BHP 14-9)CVCL_6280 (BHP 15-3)CVCL_6281 (BHP 17-10)
CVCL_6282 (BHP 18-21)CVCL_6284 (BHP 5-16)CVCL_3934 (COLO 38)
CVCL_A779 (M14-A)CVCL_ZZ71 (M14-CDM)CVCL_0417 (MDA-MB-435)
CVCL_3448 (MuM-2C)CVCL_0467 (NPA)CVCL_6934 (OCM-1)
Originate from same individual CVCL_DI53 ! MF14
CVCL_DI50 ! ML14
Sex of cell Male
Age at sampling 33Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=905975; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=28940260


Run an STR similarity search on this cell line
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm

PubMed=56444; DOI=10.1093/jnci/56.1.167
Golub S.H., Hanson D.C., Sulit H.L., Morton D.L., Pellegrino M.A., Ferrone S.
Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity.
J. Natl. Cancer Inst. 56:167-170(1976)

Zielske J.V., Golub S.H.
Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes.
Cancer Res. 36:3842-3846(1976)

PubMed=945229; DOI=10.1002/ijc.2910170408
Sulit H.L., Golub S.H., Irie R.F., Gupta R.K., Grooms G.A., Morton D.L.
Human tumor cells grown in fetal calf serum and human serum: influences on the tests for lymphocyte cytotoxicity, serum blocking and serum arming effects.
Int. J. Cancer 17:461-468(1976)

Chee D.O., Boddie A.W. Jr., Roth J.A., Holmes E.C., Morton D.L.
Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
Cancer Res. 36:1503-1509(1976)

PubMed=204583; DOI=10.1002/ijc.2910210308
Saxton R.E., Irie R.F., Ferrone S., Pellegrino M.A., Morton D.L.
Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
Int. J. Cancer 21:299-306(1978)

PubMed=6876798; DOI=10.1002/jso.2930230404
Chee D.O., Gupta R.K., Morton D.L.
Humoral response of melanoma patients to two different tumor-associated antigens.
J. Surg. Oncol. 23:228-235(1983)

PubMed=6470027; DOI=10.1007/BF00402467
Katano M., Saxton R.E., Cochran A.J., Irie R.F.
Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice.
J. Cancer Res. Clin. Oncol. 108:197-203(1984)

PubMed=6500744; DOI=10.1002/ijc.2910340511
Ferrini U., Falcioni R., Delpino A., Cavaliere R., Zupi G., Natali P.G.
Heat-shock proteins produced by two human melanoma cell lines: absence of correlation with thermosensitivity.
Int. J. Cancer 34:651-655(1984)

PubMed=3658923; DOI=10.1016/0143-4004(87)90053-1
Takahashi H., Adachi S., Yoshiya N., Suzuki T., Kanazawa K., Takeuchi S.
Expression of HLA-DR molecules in human gestational choriocarcinoma cell lines and malignant cell lines.
Placenta 8:293-298(1987)

Greco C., Zupi G.
Biological features and in vitro chemosensitivity of a new model of human melanoma.
Anticancer Res. 7:839-844(1987)

PubMed=3046746; DOI=10.1007/BF00200019
Wong J.H., Aguero B., Gupta R.K., Morton D.L.
Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.
Cancer Immunol. Immunother. 27:142-146(1988)

PubMed=1918136; DOI=10.1083/jcb.115.1.191
Quax P.H.A., van Muijen G.N.P., Weening-Verhoeff E.J.D., Lund L.R., Dano K., Ruiter D.J., Verheijen J.H.
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
J. Cell Biol. 115:191-199(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=2060184; DOI=10.1007/BF01753729
van Muijen G.N.P., Cornelissen I.L.M.H.A., Jansen K.F.J., Figdor C.G., Johnson J.P., Brocker E.-B., Ruiter D.J.
Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice.
Clin. Exp. Metastasis 9:259-272(1991)

PubMed=8618233; DOI=10.1093/jnci/88.7.419
Leonetti C., D'Agnano I., Lozupone F., Valentini A., Geiser T., Zon G., Calabretta B., Citro G., Zupi G.
Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
J. Natl. Cancer Inst. 88:419-429(1996)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=11121133; DOI=10.1046/j.1523-1747.2000.00199.x
Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C., Falcinelli S., Zambruno G., D'Atri S.
Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.
J. Invest. Dermatol. 115:1000-1007(2000)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19549886; DOI=10.1158/0008-5472.CAN-09-1528
Chambers A.F.
MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?
Cancer Res. 69:5292-5293(2009)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

PubMed=19799798; DOI=10.1186/1471-2407-9-352
Casula M., Muggiano A., Cossu A., Budroni M., Caraco C., Ascierto P.A., Pagani E., Stanganelli I., Canzanella S., Sini M.C., Palomba G., Palmieri G.
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
BMC Cancer 9:352.1-352.11(2009)

Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21863025; DOI=10.1038/bjc.2011.324
De Luca A., Lamura L., Strizzi L., Roma C., D'Antonio A., Margaryan N.V., Pirozzi G., Hsu M.-Y., Botti G., Mari E., Hendrix M.J.C., Salomon D.S., Normanno N.
Expression and functional role of CRIPTO-1 in cutaneous melanoma.
Br. J. Cancer 105:1030-1038(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28940260; DOI=10.1002/ijc.31067
Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C., Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A.
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
Int. J. Cancer 142:561-572(2017)

PubMed=29492214; DOI=10.18632/oncotarget.23989
Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.
Genetic alterations in main candidate genes during melanoma progression.
Oncotarget 9:8531-8541(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

Cell line collections (Providers) CLS; 302163
Cell line databases/resources cancercelllines; CVCL_1395
Cell_Model_Passport; SIDM00003
Cosmic-CLP; 905975
DepMap; ACH-002159
Anatomy/cell type resources BTO; BTO:0002805
Biological sample resources BioSample; SAMN06129842
Chemistry resources ChEMBL-Cells; CHEMBL3307591
ChEMBL-Targets; CHEMBL614317
GDSC; 905975
PharmacoDB; M14_879_2019
PubChem_Cell_line; CVCL_1395
Encyclopedic resources Wikidata; Q51838638
Experimental variables resources EFO; EFO_0003056
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM2140
GEO; GSM50201
GEO; GSM50263
GEO; GSM188222
GEO; GSM188252
GEO; GSM188311
GEO; GSM743464
GEO; GSM750799
GEO; GSM799352
GEO; GSM799415
GEO; GSM847034
GEO; GSM844583
GEO; GSM1153422
GEO; GSM1178326
GEO; GSM1178327
GEO; GSM1181292
GEO; GSM1181336
GEO; GSM1670072
GEO; GSM2124668
Polymorphism and mutation databases Cosmic; 686479
Cosmic; 687445
Cosmic; 875889
Cosmic; 897467
Cosmic; 905975
Cosmic; 974068
Cosmic; 974261
Cosmic; 1022278
Cosmic; 1044265
Cosmic; 1092611
Cosmic; 1109808
Cosmic; 1132591
Cosmic; 1158815
Cosmic; 1295340
Cosmic; 1303040
Cosmic; 1305365
Cosmic; 1312348
Cosmic; 1459642
Cosmic; 1537485
Cosmic; 1888913
Cosmic; 1998453
Cosmic; 2791112
IARC_TP53; 18085
Progenetix; CVCL_1395
Proteomic databases PRIDE; PXD005940
PRIDE; PXD005942
PRIDE; PXD005946
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number40